UPDATE 1-COVID vaccine developer Codiak files for US bankruptcy protection

Reuters

Mar 27, 2023

(Adds background)

March 27 (Reuters) - Codiak BioSciences Inc said on Monday it has filed for Chapter 11 bankruptcy protection and will seek to sell its assets, months after the COVID-19 vaccine developer announced job cuts.

The company reduced its workforce by 37% to 53 full-time employees in August last year to extend its cash runway. As of Sept. 30, 2022 the company had cash and cash equivalents of $51.8 million.

Codiak previously said it would prioritize its coronavirus vaccine development program that was funded by the Coalition for Epidemic Preparedness Innovations.

The company said on Monday its executive management team will leave the firm effective April 7.

(Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2322440091"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2322440091\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2322440091?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-03-27 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2322440091","market":"us","top_or_hot":-1,"title":"UPDATE 1-COVID vaccine developer Codiak files for US bankruptcy protection","media":"Reuters","content":"<html><body><p>(Adds background)</p><p>      March 27 (Reuters) - Codiak BioSciences Inc    said on Monday it has filed for Chapter 11 bankruptcy protection and will seek to sell its assets, months after the COVID-19 vaccine developer announced job cuts.</p><p>   The company reduced its workforce by 37% to 53 full-time employees in August last year to extend its cash runway. As of Sept. 30, 2022 the company had cash and cash equivalents of $51.8 million.</p><p>   Codiak previously said it would prioritize its coronavirus vaccine development program that was funded by the Coalition for Epidemic Preparedness Innovations.</p><p>   The company said on Monday its executive management team will leave the firm effective April 7.</p><p> (Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)</p><p>((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-COVID vaccine developer Codiak files for US bankruptcy protection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-COVID vaccine developer Codiak files for US bankruptcy protection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2023-03-27 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Adds background)</p><p>      March 27 (Reuters) - Codiak BioSciences Inc    said on Monday it has filed for Chapter 11 bankruptcy protection and will seek to sell its assets, months after the COVID-19 vaccine developer announced job cuts.</p><p>   The company reduced its workforce by 37% to 53 full-time employees in August last year to extend its cash runway. As of Sept. 30, 2022 the company had cash and cash equivalents of $51.8 million.</p><p>   Codiak previously said it would prioritize its coronavirus vaccine development program that was funded by the Coalition for Epidemic Preparedness Innovations.</p><p>   The company said on Monday its executive management team will leave the firm effective April 7.</p><p> (Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)</p><p>((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2322440091","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2322440091","pubTimestamp":1679916873,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"(Adds background)      March 27 (Reuters) - Codiak BioSciences Inc    said on Monday it has filed fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"更新1-COVID疫苗开发商Codiak申请美国破产保护","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDAK":0.9},"content_text":"(Adds background)      March 27 (Reuters) - Codiak BioSciences Inc    said on Monday it has filed for Chapter 11 bankruptcy protection and will seek to sell its assets, months after the COVID-19 vaccine developer announced job cuts.   The company reduced its workforce by 37% to 53 full-time employees in August last year to extend its cash runway. As of Sept. 30, 2022 the company had cash and cash equivalents of $51.8 million.   Codiak previously said it would prioritize its coronavirus vaccine development program that was funded by the Coalition for Epidemic Preparedness Innovations.   The company said on Monday its executive management team will leave the firm effective April 7. (Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}